Treatment with PCSK9 inhibitors induces a more anti-atherogenic HDL lipid profile in patients at high cardiovascular risk

Background: The COVID-19 pandemic is a serious global health problem. In Italy, to limit the infections, the government ordered lockdown from March 2020. This measure, designed to contain the virus, led to serious limitations on the daily life of the individuals it affected, and in particular in the limitation of physical exercise. The aim of this study was to evaluate the effects of reduced physical activity on the lipid profile in patients with high cardiovascular risk. Methods: We enrolled 38 dyslipidemic patients, 56% male, with an age range of 44–62 years, considered to be at high cardiovascular risk. All patients were prescribed statin drug therapy (atorvastatin 40 mg) and a vigorous physical activity program four times a week, 1 h per session. In addition, a personalized Mediterranean diet was prescribed to all the patients. Total cholesterol, LDL, HDL and triglycerides were measured in patients at T0 before lockdown and at T1 during lockdown. Results: Data showed a significant increase (p < 0.01) in total cholesterol (+6,8%) and LDL (+15,8%). Furthermore, the analysis of the data revealed a reduction in HDL (−3%) and an increase in triglycerides (+3,2%), although both were not significant (p > 0.05). Conclusions: Our study showed that the reduction in physical activity during lockdown led to an increase in LDL levels, and therefore, in the risk of ischemic heart disease in dyslipidemic patients with high cardiovascular risk.

Download Full-text

Quality Of Life Improvement In High And Very High Cardiovascular Risk Patients Treated With Pcsk9 Inhibitors

Atherosclerosis ◽

10.1016/j.atherosclerosis.2019.06.605 ◽

2019 ◽

Vol 287 ◽

pp. e199

Author(s):

A. Cesaro ◽

F. Gragnano ◽

F. Fimiani ◽

E. Moscarella ◽

I. Pariggiano ◽

...

Keyword(s):

Quality Of Life ◽

Cardiovascular Risk ◽

High Cardiovascular Risk ◽

Pcsk9 Inhibitors ◽

Risk Patients ◽

Life Improvement ◽

Very High

Download Full-text

Real-World Effectiveness of Therapy With Rosuvastatin Combined With Fenofibric Acid in a Sample of Colombian Patients With Mixed Dyslipidemia

Journal of Primary Care & Community Health ◽

10.1177/2150132720977733 ◽

2020 ◽

Vol 11 ◽

pp. 215013272097773

Author(s):

Manuel E. Machado-Duque ◽

Andrés Gaviria-Mendoza ◽

Jorge E. Machado-Alba

Keyword(s):

Cardiovascular Risk ◽

High Risk ◽

Lipid Profile ◽

Ldl Cholesterol ◽

Clinical Laboratory ◽

Lower Probability ◽

Fenofibric Acid ◽

High Cardiovascular Risk ◽

Mixed Dyslipidemia ◽

Very High

Background Ischemic heart disease is the leading cause of death in the world and is associated with dyslipidemia, high blood pressure, diabetes mellitus, and other factors. Objective To determine the clinical effectiveness on the lipid profile of the rosuvastatin + fenofibric acid combination in Colombian patients with high cardiovascular risk and mixed dyslipidemia. Methods Longitudinal observational study in a random sample of patients with a diagnosis of mixed dyslipidemia and moderate, high, or very high cardiovascular risk who were treated with rosuvastatin + fenofibric acid. Anthropometric, clinical, laboratory, comorbidity, and pharmacological variables were identified. Effectiveness on the lipid profile was determined. Results A total of 386 patients were analyzed. They had a mean age of 60.8 ± 11.4 years, 53.1% were female, and 75.6% had high/very high cardiovascular risk. The initial evaluation showed a mean LDL cholesterol of 138.4 ± 67.1 mg/dL and triglycerides of 679.7 ± 573.6 mg/dL. At the end of follow-up, mean LDL cholesterol was 87.5 ± 41.2 mg/dL (reduced by 43.3%; P < .001), and triglycerides were 243.5 ± 170.5 mg/dL (reduced by 64.2%; P < .001). Only 35.4% (n = 73) of patients with very high risk reached the goal of metabolic control, compared to 61.6% (n = 53) with high risk and 55.4% (n = 46) with moderate risk. Belonging to the very high-risk group was associated with a lower probability of achieving the control goal (OR: 0.32; 95%CI: 0.192-0.539). Conclusion The combination of rosuvastatin + fenofibric acid is an effective option in patients with mixed dyslipidemia and high cardiovascular risk, providing a therapeutic alternative for those conditions that require it.

Download Full-text

Prevention starts from the crib: the pediatric point of view on detection of families at high cardiovascular risk

Italian Journal of Pediatrics ◽

10.1186/s13052-021-00985-x ◽

2021 ◽

Vol 47 (1) ◽

Author(s):

Maria Elena Capra ◽

Cristina Pederiva ◽

Giuseppe Banderali ◽

Giacomo Biasucci

Keyword(s):

Cardiovascular Risk ◽

Family History ◽

High Risk ◽

Lipid Profile ◽

Positive Family History ◽

City Hospital ◽

High Cardiovascular Risk ◽

Cvd Risk ◽

Lipid Disorders ◽

Second Degree

Abstract Background Cardiovascular disease (CVD) is one of the main causes of mortality and morbidity in Italy. Hypercholesterolemia is a modifiable CVD risk factor. The detection and treatment of hypercholesterolemia can modify the natural history of CVD, making CVD risk for affected patients comparable to that of unaffected ones. In this scenario, the detection of families at high cardiovascular risk is the first step of CVD prevention. This multicenter, observational study is aimed at finding an effective and non-invasive screening strategy to detect families at high risk for CVD. Methods A survey investigating the knowledge of lipid and CVD issues was distributed to the parents of all infants born at the Neonatology Unit of Piacenza City Hospital and San Paolo Hospital in Milan over a 6 months period. Overall, 554 surveys have been collected. Results 26.8% newborns had parents who knew their own lipid profile, 40.2% had parents who knew the correct normal blood values of total cholesterol, 37.1% had parents who declared to have first or second degree relatives with lipid disorders, 33.7% had parents who declared to have first or second degree relatives with premature CVD Conclusion Collecting a problem-tailored and accurate family history seems to be a good strategy to detect high risk families. Our data suggest that the percentage of adults who are unaware of their lipid profile, with a positive family history for CVD and/or lipid disorders is higher than expected. As a result, even the number of undetected paediatric patients at high cardiovascular risk might be greater than expected.

Download Full-text